Study supports stent-shunt for refractory ascites
This article was originally published in Clinica
Transjugular intrahepatic portosystemic stent-shunting is an effective treatment for patients with liver cirrhosis and refractory ascites, according to a German study. Researchers from Albert Ludwig University in Freiburg used J&J's Palmaz-Schatz stent and Schneider's Wallstent in 50 of 62 consecutive patients in an uncontrolled prospective study (New England Journal of Medicine, May 4th).
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.